{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:09:10Z","timestamp":1778238550043,"version":"3.51.4"},"reference-count":127,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDB\/04138\/2020"],"award-info":[{"award-number":["UIDB\/04138\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDP\/04138\/2020"],"award-info":[{"award-number":["UIDP\/04138\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["2020.05735.BD"],"award-info":[{"award-number":["2020.05735.BD"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SFRH\/BD\/137459\/2018"],"award-info":[{"award-number":["SFRH\/BD\/137459\/2018"]}]},{"name":"fellowships","award":["UIDB\/04138\/2020"],"award-info":[{"award-number":["UIDB\/04138\/2020"]}]},{"name":"fellowships","award":["UIDP\/04138\/2020"],"award-info":[{"award-number":["UIDP\/04138\/2020"]}]},{"name":"fellowships","award":["2020.05735.BD"],"award-info":[{"award-number":["2020.05735.BD"]}]},{"name":"fellowships","award":["SFRH\/BD\/137459\/2018"],"award-info":[{"award-number":["SFRH\/BD\/137459\/2018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Mycobacterium tuberculosis (Mtb) is the etiological agent of tuberculosis (TB), a disease that, although preventable and curable, remains a global epidemic due to the emergence of resistance and a latent form responsible for a long period of treatment. Drug discovery in TB is a challenging task due to the heterogeneity of the disease, the emergence of resistance, and uncomplete knowledge of the pathophysiology of the disease. The limited permeability of the cell wall and the presence of multiple efflux pumps remain a major barrier to achieve effective intracellular drug accumulation. While the complete genome sequence of Mtb has been determined and several potential protein targets have been validated, the lack of adequate models for in vitro and in vivo studies is a limiting factor in TB drug discovery programs. In current therapeutic regimens, less than 0.5% of bacterial proteins are targeted during the biosynthesis of the cell wall and the energetic metabolism of two of the most important processes exploited for TB chemotherapeutics. This review provides an overview on the current challenges in TB drug discovery and emerging Mtb druggable proteins, and explains how chemical probes for protein profiling enabled the identification of new targets and biomarkers, paving the way to disruptive therapeutic regimens and diagnostic tools.<\/jats:p>","DOI":"10.3390\/ijms241310482","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T01:54:56Z","timestamp":1687485296000},"page":"10482","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Target Identification in Anti-Tuberculosis Drug Discovery"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9637-3714","authenticated-orcid":false,"given":"Rita","family":"Capela","sequence":"first","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-0822","authenticated-orcid":false,"given":"Rita","family":"F\u00e9lix","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-6290","authenticated-orcid":false,"given":"Marta","family":"Clariano","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1072-4451","authenticated-orcid":false,"given":"Diogo","family":"Nunes","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]},{"given":"Maria de Jesus","family":"Perry","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5350-147X","authenticated-orcid":false,"given":"Francisca","family":"Lopes","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrmicro.2018.8","article-title":"Ecology and evolution of Mycobacterium tuberculosis","volume":"16","author":"Gagneux","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","first-page":"7-4","article-title":"Mycobacterium tuberculosis Metabolism","volume":"7","year":"2019","journal-title":"Microbiol. Spectr."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Woodman, M., Haeusler, I.L., and Grandjean, L. (2019). Tuberculosis Genetic Epidemiology: A Latin American Perspective. Genes, 10.","DOI":"10.3390\/genes10010053"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14745\/ccdr.v43i34a01","article-title":"Latent tuberculosis infection: An overview","volume":"43","author":"Kiazyk","year":"2017","journal-title":"Can. Commun. Dis. Rep."},{"key":"ref_5","unstructured":"World Health Organization (2022). Global Tuberculosis Report 2022, World Health Organization."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ejmech.2018.03.020","article-title":"Drug discovery in tuberculosis. New drug targets and antimycobacterial agents","volume":"150","author":"Moreira","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: Progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(19)30024-8","article-title":"Building a tuberculosis-free world: The Lancet Commission on tuberculosis","volume":"393","author":"Reid","year":"2019","journal-title":"Lancet"},{"key":"ref_9","first-page":"1","article-title":"Preclinical Efficacy Testing of New Drug Candidates","volume":"5","year":"2017","journal-title":"Microbiol. Spectr."},{"key":"ref_10","first-page":"22","article-title":"Recent and New Strategies for Extensively Drug-Resistant Tuberculosis","volume":"7","year":"2018","journal-title":"Mediterr. J. Infect. Microbes Antimicrob."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/23744235.2017.1377346","article-title":"Drug targets in dormant Mycobacterium tuberculosis: Can the conquest against tuberculosis become a reality?","volume":"50","author":"Gupta","year":"2018","journal-title":"Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ardp.202200214","article-title":"Drug re-engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery","volume":"355","author":"Reddy","year":"2022","journal-title":"Arch. Der Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Macalino, S.J.Y., Billones, J.B., Organo, V.G., and Carrillo, M.C.O. (2020). In Silico Strategies in Tuberculosis Drug Discovery. Molecules, 25.","DOI":"10.3390\/molecules25030665"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.drudis.2020.02.003","article-title":"The quest for the holy grail: New antitubercular chemical entities, targets and strategies","volume":"25","author":"Chibale","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jgar.2017.10.006","article-title":"Drug-resistant Mycobacterium tuberculosis: Epidemiology and role of morphological alterations","volume":"12","author":"Velayati","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1128\/AAC.02202-12","article-title":"Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis","volume":"57","author":"Sarathy","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17460441.2017.1255604","article-title":"Current challenges in drug discovery for tuberculosis","volume":"12","author":"Kumar","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Li, X.-Z., Elkins, C.A., and Zgurskaya, H.I. (2016). Efflux-Mediated Antimicrobial Resistance in Bacteria: Mechanisms, Regulation and Clinical Implications, Springer International Publishing.","DOI":"10.1007\/978-3-319-39658-3"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17084","DOI":"10.1038\/nmicrobiol.2017.84","article-title":"Metabolic anticipation in Mycobacterium tuberculosis","volume":"2","author":"Eoh","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"871464","DOI":"10.3389\/fmicb.2022.871464","article-title":"Editorial: Approaches to Address Resistance, Drug Discovery, and Vaccine Development in Mycobacterium tuberculosis: Challenges and Opportunities","volume":"13","author":"Sharma","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"932556","DOI":"10.3389\/fcimb.2022.932556","article-title":"Failing upwards: Genetics-based strategies to improve antibiotic discovery and efficacy in Mycobacterium tuberculosis","volume":"12","author":"Tomasi","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"00681","DOI":"10.3389\/fphar.2017.00681","article-title":"Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach","volume":"8","author":"Mugumbate","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/emmm.201201772","article-title":"Tuberculosis drug discovery in the post-post-genomic era","volume":"6","author":"Lechartier","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.drudis.2016.11.014","article-title":"Target-based approaches for the discovery of new antimycobacterial drugs","volume":"22","author":"Borsari","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1128\/AAC.00055-06","article-title":"Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosis","volume":"51","author":"Sang","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/iai.64.6.2062-2069.1996","article-title":"An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence","volume":"64","author":"Wayne","year":"1996","journal-title":"Infect. Immun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1128\/AAC.01125-12","article-title":"Streptomycin-Starved Mycobacterium tuberculosis 18b, a Drug Discovery Tool for Latent Tuberculosis","volume":"56","author":"Zhang","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Darby, C.M., Ing\u00f3lfsson, H.I., Jiang, X., Shen, C., Sun, M., Zhao, N., Burns, K., Liu, G., Ehrt, S., and Warren, J.D. (2013). Whole Cell Screen for Inhibitors of pH Homeostasis in Mycobacterium tuberculosis. PLoS ONE, 8.","DOI":"10.1371\/annotation\/760b5b07-4922-42c4-b33a-162c1e9ae188"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Parish, T., and Kumar, A. (2021). Mycobacteria Protocols, Springer.","DOI":"10.1007\/978-1-0716-1460-0"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1099\/jmm.0.000681","article-title":"Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions","volume":"67","author":"Cnockaert","year":"2018","journal-title":"J. Med. Microbiol."},{"key":"ref_31","first-page":"E2510","article-title":"Identification of a small molecule with activity against drug-resistant and persistent tuberculosis","volume":"110","author":"Wang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Egorova, A., Salina, E.G., and Makarov, V. (2021). Targeting Non-Replicating Mycobacterium tuberculosis and Latent Infection: Alternatives and Perspectives (Mini-Review). Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413317"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: Challenges and priorities","volume":"20","author":"Dartois","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"114906","DOI":"10.1016\/j.bcp.2021.114906","article-title":"Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery","volume":"197","author":"Perveen","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1039\/D0MD00261E","article-title":"Mycobacterial drug discovery","volume":"11","author":"Abrahams","year":"2020","journal-title":"RSC Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1056608","DOI":"10.3389\/fmicb.2022.1056608","article-title":"Anti-tuberculosis drug development via targeting the cell envelope of Mycobacterium tuberculosis","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trsl.2020.03.007","article-title":"New tuberculosis drug targets, their inhibitors, and potential therapeutic impact","volume":"220","author":"Shetye","year":"2020","journal-title":"Transl. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/mmi.13101","article-title":"Mycolic acids: Deciphering and targeting the Achilles\u2019 heel of the tubercle bacillus","volume":"98","author":"Nataraj","year":"2015","journal-title":"Mol. Microbiol."},{"key":"ref_40","first-page":"611","article-title":"The Molecular Genetics of Mycolic Acid Biosynthesis","volume":"2","author":"Kremer","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e02133-16","DOI":"10.1128\/mBio.02133-16","article-title":"Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis","volume":"8","author":"Xu","year":"2017","journal-title":"mBio"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.chembiol.2020.02.007","article-title":"A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA","volume":"27","author":"Inoyama","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"12581","DOI":"10.1038\/ncomms12581","article-title":"Identification of KasA as the cellular target of an anti-tubercular scaffold","volume":"7","author":"Abrahams","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e02101","DOI":"10.1128\/mBio.02101-17","article-title":"Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA","volume":"9","author":"Kumar","year":"2018","journal-title":"mBio"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ejmech.2016.07.009","article-title":"Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents","volume":"122","author":"Ramesh","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e202200160","DOI":"10.1002\/cbdv.202200160","article-title":"Molecular Modelling and Atomistic Insights into the Binding Mechanism of MmpL3 Mtb","volume":"19","author":"Kwofie","year":"2022","journal-title":"Chem. Biodivers."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1017\/S0031182016002377","article-title":"Mycobacterial cell wall biosynthesis: A multifaceted antibiotic target","volume":"145","author":"Abrahams","year":"2018","journal-title":"Parasitology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.aba9102","article-title":"Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"ref_49","unstructured":"Liu, H.-W., and Mander, L. (2010). Comprehensive Natural Products II, Elsevier."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s13238-020-00726-6","article-title":"Cryo-EM snapshots of mycobacterial arabinosyltransferase complex EmbB2-AcpM2","volume":"11","author":"Zhang","year":"2020","journal-title":"Protein Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1128\/AAC.00162-09","article-title":"The Arabinosyltransferase EmbC Is Inhibited by Ethambutol in Mycobacterium tuberculosis","volume":"53","author":"Goude","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1099\/mic.0.2008\/016378-0","article-title":"Partial redundancy in the synthesis of the d-arabinose incorporated in the cell wall arabinan of Corynebacterineae","volume":"154","author":"Meniche","year":"2008","journal-title":"Microbiology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/jam.13228","article-title":"Down-regulation of N-acetylglucosamine-1-phosphate transferase (WecA) enhanced the sensitivity of Mycobacterium smegmatis against rifampin","volume":"121","author":"Xu","year":"2016","journal-title":"J. Appl. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"102207","DOI":"10.1016\/j.tube.2022.102207","article-title":"Efficacy of inhaled CPZEN-45 in treating tuberculosis in the guinea pig","volume":"135","author":"Young","year":"2022","journal-title":"Tuberculosis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbrc.2022.03.091","article-title":"Functional investigation of the antitubercular drug target Decaprenylphosphoryl-\u03b2-D-ribofuranose-2-epimerase DprE1\/DprE2 complex","volume":"607","author":"Sammartino","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"14430","DOI":"10.1021\/acsomega.1c01314","article-title":"Chemical Space Exploration of DprE1 Inhibitors Using Chemoinformatics and Artificial Intelligence","volume":"6","author":"Chhabra","year":"2021","journal-title":"ACS Omega"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Iqbal, I.K., Bajeli, S., Akela, A.K., and Kumar, A. (2018). Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery. Pathogens, 7.","DOI":"10.3390\/pathogens7010024"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s11030-021-10335-y","article-title":"Targeting the cytochrome bc1 complex for drug development in M. tuberculosis: Review","volume":"26","author":"Wani","year":"2022","journal-title":"Mol. Divers."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"611683","DOI":"10.3389\/fcimb.2020.611683","article-title":"Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis","volume":"10","author":"Hasenoehrl","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"589318","DOI":"10.3389\/fcimb.2020.589318","article-title":"Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?","volume":"10","author":"Bajeli","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Foo, C.S., Pethe, K., and Lupien, A. (2020). Oxidative Phosphorylation\u2014An Update on a New, Essential Target Space for Drug Discovery in Mycobacterium tuberculosis. Appl. Sci., 10.","DOI":"10.3390\/app10072339"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Borisov, V.B., and Forte, E. (2022). Bioenergetics and Reactive Nitrogen Species in Bacteria. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137321"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41594-018-0160-3","article-title":"Structure of a functional obligate complex III2IV2 respiratory supercomplex from Mycobacterium smegmatis","volume":"25","author":"Wiseman","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_64","first-page":"e00606","article-title":"Identification of 4-Amino-Thieno [2,3-d]Pyrimidines as QcrB Inhibitors in Mycobacterium tuberculosis","volume":"4","author":"Gregory","year":"2019","journal-title":"mSphere"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lupien, A., Foo, C.S.-Y., Savina, S., Vocat, A., Piton, J., Monakhova, N., Benjak, A., Lamprecht, D.A., Steyn, A.J.C., and Pethe, K. (2020). New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008270"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Moraski, G.C., Deboos\u00e8re, N., Marshall, K.L., Weaver, H.A., Vandeputte, A., Hastings, C., Woolhiser, L., Lenaerts, A.J., Brodin, P., and Miller, M.J. (2020). Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0227224"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/17460441.2020.1696771","article-title":"Emerging opportunities of exploiting mycobacterial electron transport chain pathway for drug-resistant tuberculosis drug discovery","volume":"15","author":"Roy","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/bs.armc.2019.05.001","article-title":"Chapter Four\u2014Inhibitors of enzymes in the electron transport chain of Mycobacterium tuberculosis","volume":"Volume 52","author":"Chibale","year":"2019","journal-title":"Annual Reports in Medicinal Chemistry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1074\/jbc.RA118.005732","article-title":"Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria","volume":"294","author":"Lee","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"110782","DOI":"10.1016\/j.biopha.2020.110782","article-title":"TB47 and clofazimine form a highly synergistic sterilizing block in a second-line regimen for tuberculosis in mice","volume":"131","author":"Yu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e00706","DOI":"10.1128\/AAC.00706-21","article-title":"Sterilizing Effects of Novel Regimens Containing TB47, Clofazimine, and Linezolid in a Murine Model of Tuberculosis","volume":"65","author":"Yu","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Cai, Y., Jaecklein, E., Mackenzie, J.S., Papavinasasundaram, K., Olive, A.J., Chen, X., Steyn, A.J.C., and Sassetti, C.M. (2021). Host immunity increases Mycobacterium tuberculosis reliance on cytochrome bd oxidase. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1008911"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11030-020-10034-0","article-title":"Targeting the menaquinol binding loop of mycobacterial cytochrome bd oxidase","volume":"25","author":"Harikishore","year":"2021","journal-title":"Mol. Divers."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Friedrich, T., Wohlwend, D., and Borisov, V.B. (2022). Recent Advances in Structural Studies of Cytochrome bd and Its Potential Application as a Drug Target. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063166"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e01276-18","DOI":"10.1128\/mBio.01276-18","article-title":"Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis","volume":"9","author":"Lupien","year":"2018","journal-title":"mBio"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e01338-17","DOI":"10.1128\/AAC.01338-17","article-title":"Susceptibility of Mycobacterium tuberculosis Cytochrome bd Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c","volume":"61","author":"Moosa","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Sarathy, J.P., Gruber, G., and Dick, T. (2019). Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline. Antibiotics, 8.","DOI":"10.3390\/antibiotics8040261"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"104509","DOI":"10.1016\/j.biosystems.2021.104509","article-title":"Study of the bioenergetics to identify the novel pathways as a drug target against Mycobacterium tuberculosis using Petri net","volume":"209","author":"Gupta","year":"2021","journal-title":"Biosystems"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s41598-018-38064-7","article-title":"2-aminoimidazoles collapse mycobacterial proton motive force and block the electron transport chain","volume":"9","author":"Jeon","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1021\/acsomega.7b00892","article-title":"In Vitro Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium tuberculosis","volume":"2","author":"Odingo","year":"2017","journal-title":"ACS Omega"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1021\/acs.chemrev.8b00285","article-title":"Iron Acquisition in Mycobacterium tuberculosis","volume":"119","author":"Chao","year":"2019","journal-title":"Chem. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ejmech.2018.06.033","article-title":"Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents","volume":"155","author":"Chiarelli","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14756366.2019.1589462","article-title":"New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents","volume":"34","author":"Chiarelli","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1038\/s41598-017-04748-9","article-title":"Virtual Screening, pharmacophore development and structure based similarity search to identify inhibitors against IdeR, a transcription factor of Mycobacterium tuberculosis","volume":"7","author":"Rohilla","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.drudis.2021.09.003","article-title":"Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors","volume":"27","author":"Yang","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152607781001763","article-title":"Mycobacterium tuberculosis DNA Gyrase as a Target for Drug Discovery","volume":"7","author":"Khisimuzi","year":"2007","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.biopha.2018.04.021","article-title":"DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents","volume":"103","author":"Khan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.04516-14","article-title":"Targeting Mycobacterium tuberculosis Topoisomerase I by Small-Molecule Inhibitors","volume":"59","author":"Ahmed","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/med.20114","article-title":"NAD+-Dependent DNA Ligase: A novel target waiting for the right inhibitor","volume":"28","author":"Dwivedi","year":"2008","journal-title":"Med. Res. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"30273","DOI":"10.1074\/jbc.M503780200","article-title":"NAD+-dependent DNA Ligase (Rv3014c) from Mycobacterium tuberculosis: Crystal structure of the adenylation domain and identification of novel inhibitors*","volume":"280","author":"Srivastava","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1080\/14756366.2019.1662790","article-title":"1-(Piperidin-3-yl)thymine amides as inhibitors of M. tuberculosis thymidylate kinase","volume":"34","author":"Jian","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.1039\/D1SC01359A","article-title":"Recent advances in activity-based probes (ABPs) and affinity-based probes (AfBPs) for profiling of enzymes","volume":"12","author":"Fang","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nature12790","article-title":"Activated ClpP kills persisters and eradicates a chronic biofilm infection","volume":"503","author":"Conlon","year":"2013","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nm.1795","article-title":"A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis","volume":"14","author":"Vandal","year":"2008","journal-title":"Nat. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"11051","DOI":"10.1074\/jbc.R109.097600","article-title":"Activity-based Proteomics of Enzyme Superfamilies: Serine Hydrolases as a Case Study","volume":"285","author":"Simon","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.chembiol.2016.01.003","article-title":"Systematic Survey of Serine Hydrolase Activity in Mycobacterium tuberculosis Defines Changes Associated with Persistence","volume":"23","author":"Ortega","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"20941","DOI":"10.1073\/pnas.1011663107","article-title":"Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening","volume":"107","author":"Bachovchin","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/acsinfecdis.6b00092","article-title":"Design of Selective Substrates and Activity-Based Probes for Hydrolase Important for Pathogenesis 1 (HIP1) from Mycobacterium tuberculosis","volume":"2","author":"Lentz","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.chembiol.2021.08.013","article-title":"Identification of covalent inhibitors that disrupt M. tuberculosis growth by targeting multiple serine hydrolases involved in lipid metabolism","volume":"29","author":"Babin","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.chembiol.2021.09.002","article-title":"Identification of cell wall synthesis inhibitors active against Mycobacterium tuberculosis by competitive activity-based protein profiling","volume":"29","author":"Li","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2217\/fmb-2019-0318","article-title":"Tuberculosis and beta-lactam antibiotics","volume":"15","author":"Gun","year":"2020","journal-title":"Future Microbiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"807955","DOI":"10.3389\/fmicb.2022.807955","article-title":"The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition","volume":"13","author":"Turner","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3389\/fmicb.2020.01248","article-title":"Activity-Based Protein Profiling Reveals That Cephalosporins Selectively Active on Non-replicating Mycobacterium tuberculosis Bind Multiple Protein Families and Spare Peptidoglycan Transpeptidases","volume":"11","author":"Smith","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/cbic.201900379","article-title":"A Fluorescence-Based Assay for Screening \u03b2-Lactams Targeting the Mycobacterium tuberculosis Transpeptidase LdtMt2","volume":"21","author":"Lohans","year":"2020","journal-title":"ChemBioChem"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acsinfecdis.0c00809","article-title":"Investigating \u03b2-Lactam Drug Targets in Mycobacterium tuberculosis Using Chemical Probes","volume":"7","author":"Levine","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/anie.201709365","article-title":"An Antibacterial \u03b2-Lactone Kills Mycobacterium tuberculosis by Disrupting Mycolic Acid Biosynthesis","volume":"57","author":"Lehmann","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1074\/mcp.M113.029942","article-title":"Targeting Lipid Esterases in Mycobacteria Grown Under Different Physiological Conditions Using Activity-based Profiling with Tetrahydrolipstatin (THL)","volume":"13","author":"Ravindran","year":"2014","journal-title":"Mol. Cell. Proteom."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cbic.201402548","article-title":"Far-red fluorogenic probes for esterase and lipase detection","volume":"16","author":"Tallman","year":"2015","journal-title":"Chembiochem A Eur. J. Chem. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1021\/acsinfecdis.6b00135","article-title":"Small-Molecule Probes Reveal Esterases with Persistent Activity in Dormant and Reactivating Mycobacterium tuberculosis","volume":"2","author":"Tallman","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1021\/acschembio.6b00233","article-title":"Profiling Esterases in Mycobacterium tuberculosis Using Far-Red Fluorogenic Substrates","volume":"11","author":"Tallman","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/JB.02015-14","article-title":"The rv1184c Locus Encodes Chp2, an Acyltransferase in Mycobacterium tuberculosis Polyacyltrehalose Lipid Biosynthesis","volume":"197","year":"2015","journal-title":"J. Bacteriol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"27952","DOI":"10.1074\/jbc.M114.581199","article-title":"Biosynthesis and Translocation of Unsulfated Acyltrehaloses in Mycobacterium tuberculosis","volume":"289","author":"Belardinelli","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1074\/jbc.M111.315473","article-title":"Elucidation and Chemical Modulation of Sulfolipid-1 Biosynthesis in Mycobacterium tuberculosis*","volume":"287","author":"Seeliger","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Cravatt, B.F., Hsu, K.-L., and Weerapana, E. (2019). Activity-Based Protein Profiling, Springer International Publishing.","DOI":"10.1007\/978-3-030-11143-4"},{"key":"ref_115","first-page":"791728","article-title":"Roles of Mucosal Immunity against Mycobacterium tuberculosis Infection","volume":"2012","author":"Li","year":"2012","journal-title":"Tuberc. Res. Treat."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4161\/gmic.1.4.12778","article-title":"Mucin-bacterial interactions in the human oral cavity and digestive tract","volume":"1","author":"Derrien","year":"2010","journal-title":"Gut Microbes"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"17037","DOI":"10.1073\/pnas.252514899","article-title":"Discovery of sulfated metabolites in mycobacteria with a genetic and mass spectrometric approach","volume":"99","author":"Mougous","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molcel.2005.10.034","article-title":"Molecular Basis for G Protein Control of the Prokaryotic ATP Sulfurylase","volume":"21","author":"Mougous","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13568-017-0449-3","article-title":"Detection of bacterial sulfatase activity through liquid- and solid-phase colony-based assays","volume":"7","author":"Yoon","year":"2017","journal-title":"AMB Express"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1021\/cb300112x","article-title":"Development of a Selective Activity-Based Probe for Adenylating Enzymes: Profiling MbtA Involved in Siderophore Biosynthesis from Mycobacterium tuberculosis","volume":"7","author":"Duckworth","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1074\/mcp.M112.025635","article-title":"A chemical proteomics approach to profiling the ATP-binding proteome of Mycobacterium tuberculosis","volume":"12","author":"Wolfe","year":"2013","journal-title":"Mol. Cell. Proteom."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1042\/BCJ20200194","article-title":"The thick waxy coat of mycobacteria, a protective layer against antibiotics and the host\u2019s immune system","volume":"477","author":"Batt","year":"2020","journal-title":"Biochem. J."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Vilch\u00e8ze, C. (2020). Mycobacterial Cell Wall: A Source of Successful Targets for Old and New Drugs. Appl. Sci., 10.","DOI":"10.3390\/app10072278"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/id500032q","article-title":"Covalent Modification of the Mycobacterium tuberculosis FAS-II Dehydratase by Isoxyl and Thiacetazone","volume":"1","author":"Grzegorzewicz","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1039\/D1OB02080C","article-title":"Fluorescently labelled thioacetazone for detecting the interaction with Mycobacterium dehydratases HadAB and HadBC","volume":"20","author":"Singh","year":"2022","journal-title":"Org. Biomol. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2150449","DOI":"10.1080\/21505594.2022.2150449","article-title":"Pathogenicity and virulence of Mycobacterium tuberculosis","volume":"14","author":"Rahlwes","year":"2023","journal-title":"Virulence"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1039\/C2OB27257A","article-title":"Development of a benzophenone and alkyne functionalised trehalose probe to study trehalose dimycolate binding proteins","volume":"11","author":"Khan","year":"2013","journal-title":"Org. Biomol. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10482\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:58:32Z","timestamp":1760126312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":127,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241310482"],"URL":"https:\/\/doi.org\/10.3390\/ijms241310482","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]}}}